Alnylam Announces FDA Approval of Supplemental New Drug Appl

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , Christine Regan Lindenboom , Jorge Capapey , Josh Brodsky , Kim Hollander , Instagram , Linkedin , Hyperoxaluria Foundation , Global Rare Disease Lead At Alnylam Pharmaceuticals , Drug Administration , Alnylam Pharmaceuticals Inc , Nasdaq , Novartis , Exchange Commission , Alnylam Pharmaceuticals , European Medicines Agency , Committee For Medicinal Products Human Use , Primary Hyperoxaluria Type , Lower Urinary , Plasma Oxalate Levels , Adult Patients , Positive Efficacy , Safety Results , Severe Renal Impairment , Including Those , New Drug Application , Vice President , Global Rare Disease Lead , Month Six , Executive Director , Medicinal Products , Human Use , Enhanced Stabilization Chemistry , Nobel Prize Winning , Private Securities Litigation Reform Act , Quarterly Report , Bend Points , Clinical Trials , Clinj Am Soc ,